CDC Investigating New Vaccine After Multiple Hospitalizations

The Centers for Disease Control and Prevention (CDC) is now investigating five hospitalizations among elderly patients who recently received the newly approved chikungunya vaccine, IXCHIQ. The affected individuals, all 65 and older, suffered serious cardiac or neurological events shortly after vaccination, raising concerns over the vaccine’s safety.

This latest development comes amid growing skepticism surrounding rushed vaccine approvals and post-market surveillance. IXCHIQ, manufactured by the European biotech company Valneva, was fast-tracked for approval in November 2023 by the Food and Drug Administration (FDA), despite the virus posing little threat to Americans. The vaccine is primarily recommended for travelers heading to regions where chikungunya is endemic.

Rushed Approval, Questionable Need?

Chikungunya virus is spread by mosquito bites and causes fever, joint pain, and rash, but it is not considered a major public health threat in the U.S. No locally acquired cases have been reported since 2019.

Given this, critics question the necessity of the vaccine’s broad rollout. Dr. John Mitchell, a retired virologist, noted, “The CDC and FDA pushed this vaccine forward for a disease that is virtually nonexistent in America. Why? Who benefits?”

Unanswered Questions About Side Effects

The CDC initially planned to review the vaccine’s safety at the Advisory Committee on Immunization Practices (ACIP) meeting this week, but the discussion was mysteriously postponed. Health officials have not provided a new date for the review.

According to a CDC notice, “Healthcare providers should discuss the benefits and risks of vaccination with individual travelers based on their age, destination, trip duration, and planned activities.” However, the recent hospitalizations suggest the risk might be more severe than initially disclosed.

The vaccine contains a live, weakened version of the chikungunya virus, which can cause prolonged chikungunya-like reactions. The CDC acknowledges that common side effects include muscle pain, fever, nausea, and fatigue, but in rare cases, serious heart and neurological conditions have emerged.

Conflicting Reports from Manufacturer

Valneva responded to the CDC’s ongoing review by insisting there is no direct link between the vaccine and the hospitalizations. In a statement, the company said, “We understand from the CDC that at least four of these five individuals had also received other vaccines, and most of them had significant underlying medical conditions.”

Yet, vaccine safety studies conducted prior to approval indicated that 1.6% of recipients experienced severe chikungunya-like symptoms, including fever, joint pain, and neurological complications. “The CDC’s own data suggests a pattern,” said Dr. Raymond Carter, a medical analyst critical of vaccine mandates. “It’s no surprise they’re now scrambling to do damage control.”

Concerns Over Post-Marketing Surveillance

The CDC has urged healthcare providers to report adverse vaccine reactions to the Vaccine Adverse Event Reporting System (VAERS). But critics argue that VAERS is a reactive system, meaning serious safety concerns often surface only after large-scale distribution.

“With all vaccines, especially those rushed to market, post-approval monitoring is our only real safety net,” said Dr. Carter. “We’re seeing the consequences of an agency too eager to approve experimental shots before all the risks are known.”

As the investigation continues, many are left wondering: Was this another case of a vaccine pushed through without enough oversight? The CDC is expected to release further details on its findings, but for now, the questions surrounding IXCHIQ remain unanswered.